Mayne Pharma Group
Market Cap
AU$924.2m
Last Updated
2019/11/12 10:33 UTC
Data Sources
Company Financials +
Executive Summary
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally.
Snowflake
Fundamentals
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Mayne Pharma Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
10.5%
MYX
2.7%
AU Pharmaceuticals
1.2%
AU Market
1 Year Return
-48.2%
MYX
-31.8%
AU Pharmaceuticals
12.1%
AU Market
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -31.8% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 12.1% over the past year.
Shareholder returns
| MYX | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.5% | 2.7% | 1.2% |
| 30 Day | -0.9% | -0.5% | 2.0% |
| 90 Day | 19.6% | 3.5% | 3.2% |
| 1 Year | -48.2%-48.2% | -31.6%-31.8% | 18.3%12.1% |
| 3 Year | -64.7%-64.7% | -42.5%-43.1% | 40.6%22.1% |
| 5 Year | -16.7%-23.2% | -21.1%-28.2% | 54.2%19.8% |
Price Volatility Vs. Market
How volatile is Mayne Pharma Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Introducing Mayne Pharma Group (ASX:MYX), The Stock That Slid 70% In The Last Three Years4 weeks ago | Simply Wall St
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?1 month ago | Simply Wall St
What Did Mayne Pharma Group Limited's (ASX:MYX) CEO Take Home Last Year?Valuation
Is Mayne Pharma Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MYX (A$0.58) is trading below our estimate of fair value (A$1.58)
Significantly Below Fair Value: MYX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MYX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: MYX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYX is good value based on its PB Ratio (0.9x) compared to the AU Pharmaceuticals industry average (2.3x).
Next Steps
Future Growth
How is Mayne Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
97.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYX's is expected to become profitable in the next 3 years.
Revenue vs Market: MYX's revenue (11.6% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: MYX's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYX's Return on Equity is forecast to be low in 3 years time (7.1%).
Next Steps
Past Performance
How has Mayne Pharma Group performed over the past 5 years?
-51.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYX has large one-off items impacting its financial results.
Growing Profit Margin: MYX's current net profit margins (-53.5%) are lower than last year (-25.3%).
Past Earnings Growth Analysis
Earnings Trend: MYX is unprofitable, and losses have increased over the past 5 years at a rate of -51% per year.
Accelerating Growth: Unable to compare MYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.9%).
Return on Equity
High ROE: MYX has a negative Return on Equity (-27.98%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Mayne Pharma Group's financial position?
Financial Position Analysis
Short Term Liabilities: MYX's short term assets (A$471.9M) exceeds its short term liabilities (A$211.3M)
Long Term Liabilities: MYX's short term assets (471.9M) exceeds its long term liabilities (410.9M)
Debt to Equity History and Analysis
Debt Level: MYX's debt to equity ratio (36.5%) is considered satisfactory
Reducing Debt: MYX's debt to equity ratio has increased from 30.2% to 36.5% over the past 5 years.
Balance Sheet
Inventory Level: MYX has a high level of physical assets or inventory.
Debt Coverage by Assets: MYX's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MYX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MYX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 85% per year.
Next Steps
Dividend
What is Mayne Pharma Group's current dividend yield, its reliability and sustainability?
0.29%
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MYX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MYX is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Mayne Pharma Group's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Scott Richards (55yo)
7.8yrs
Tenure
AU$2,864,653
Compensation
Mr. Scott Anthony Richards has been the Chief Executive Officer and Managing Director of Mayne Pharma Group Limited since February 13, 2012. Mr. Richards joined Mayne Pharma in February 2012. He served as  ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD1.96M) is above average for companies of similar size in the Australian market ($USD981.68K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.4yrs
Average Tenure
53yo
Average Age
Experienced Management: MYX's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
7.8yrs
Average Tenure
65yo
Average Age
Experienced Board: MYX's board of directors are considered experienced (7.8 years average tenure).
Insider Trading
Insider Buying: MYX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 50,897 |
| Max Price | AU$0.59 |
| Entity | Company |
| Shares | 20,124,600 |
| Max Price | AU$0.55 |
| Entity | Company |
| Shares | 22,043,767 |
| Max Price | AU$0.63 |
| Entity | Company |
| Shares | 27,381,071 |
| Max Price | AU$0.81 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 27,272 |
| Max Price | AU$0.78 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 181,835 |
| Max Price | AU$0.77 |
| Entity | Company |
| Shares | 103,279 |
| Max Price | AU$0.95 |
| Entity | Company |
| Shares | 106,864 |
| Max Price | AU$0.91 |
| Entity | Company |
| Shares | 99,648,311 |
| Max Price | AU$1.17 |
| Entity | Company |
| Shares | 165,726 |
| Max Price | AU$1.16 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
John Ross
President of Mayne Pharma USA
- Tenure: 2.8yrs
- Compensation: AU$1.21m
Scott Richards (55yo)
MD, CEO & Executive Director
- Tenure: 7.8yrs
- Compensation: AU$2.86m
Peter Paltoglou
Chief Development Officer and Head of M&A
- Tenure: 4.3yrs
- Compensation: AU$980.15k
Nick Freeman
Group CFO & Company Secretary
- Tenure: 2.5yrs
- Compensation: AU$1.07m
Lisa Pendlebury
Vice President of Investor Relations & Communications
- Tenure: 4yrs
- Compensation: AU$456.63k
Stefan Cross (46yo)
President of International Operations
- Tenure: 2.8yrs
- Compensation: AU$1.01m
Brant Schofield (53yo)
Executive Vice President of Specialty Brands Division
- Tenure: 1.1yrs
- Compensation: AU$1.29m
Kate Rintoul
Executive VP & General Counsel
- Tenure: 6.8yrs
- Compensation: AU$767.48k
Ilana Stancovski
Chief Scientific Officer & Head of European Market Development
- Tenure: 5.2yrs
- Compensation: AU$954.15k
Andy Herdman
Vice President of Group Human Resources
- Tenure: 1.2yrs
Board Members
Ian Scholes (64yo)
Independent Non-Executive Director
- Tenure: 12.1yrs
- Compensation: AU$153.30k
Roger Corbett (76yo)
Independent Chairman
- Tenure: 8.8yrs
- Compensation: AU$303.75k
Bruce Mathieson (76yo)
Independent Non Executive Director
- Tenure: 12.8yrs
- Compensation: AU$131.40k
Scott Richards (55yo)
MD, CEO & Executive Director
- Tenure: 7.8yrs
- Compensation: AU$2.86m
Frank Condella (65yo)
Independent Non-Executive Director
- Tenure: 1.5yrs
- Compensation: AU$156.97k
Bruce Robinson (62yo)
Independent Non-Executive Director
- Tenure: 5.3yrs
- Compensation: AU$134.14k
Pat Blake (55yo)
Independent Non-Executive Director
- Tenure: 1.4yrs
- Compensation: AU$156.97k
Ron Best (70yo)
Independent Non Executive Director
- Tenure: 13.3yrs
- Compensation: AU$142.35k
Nancy Dolan (68yo)
Independent Non-Executive Director
- Tenure: 3.2yrs
- Compensation: AU$142.35k
Company Information
Mayne Pharma Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mayne Pharma Group Limited
- Ticker: MYX
- Exchange: ASX
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$924.161m
- Shares outstanding: 1.59b
- Website: https://www.maynepharma.com
Number of Employees
Location
- Mayne Pharma Group Limited
- 1538 Main North Road
- Salisbury South
- South Australia
- 5106
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MYX | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jun 2007 |
| HG6 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 2007 |
| MAYN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 2007 |
| MYX | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jun 2007 |
Biography
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. It operates t ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/12 10:33 |
| End of Day Share Price | 2019/11/12 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.